UC Irvine

UC Irvine Previously Published Works

Title

Antibody-dependent cellular cytotoxicity in HIV infection.

Permalink

<https://escholarship.org/uc/item/1kg8r2vm>

Journal

AIDS (London, England), 32(17)

ISSN

0269-9370

Authors

Forthal, Donald N
Finzi, Andrés

Publication Date

2018-11-01

DOI

10.1097/qad.0000000000002011

Peer reviewed

EDITORIAL REVIEW

Antibody-dependent cellular cytotoxicity in HIV infection

Donald N. Forthal^{a,b} and Andrés Finzi^{c,d}

Interactions between the Fc segment of IgG and its receptors (FcγRs) found on cells such as natural killer cells, monocytes, macrophages and neutrophils can potentially mediate antiviral effects in the setting of HIV and related infections. We review the potential role of Fc-FcR interactions in HIV, SIV and SHIV infections, with an emphasis on antibody-dependent cellular cytotoxicity (ADCC). Notably, these viruses employ various strategies, including CD4 down-regulation and BST-2/tetherin antagonism to limit the effect of ADCC. Although correlative data suggest that ADCC participates in both protection and control of established infection, there is little direct evidence in support of either role. Direct evidence does, however, implicate an FcγR-dependent function in augmenting the beneficial in-vivo activity of neutralizing antibodies.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

AIDS 2018, **32**:000–000

Keywords: antibody-dependent cellular cytotoxicity, CD4, Fc receptor, HIV, natural killer cell, phagocytosis, simian immunodeficiency virus, simian/human immunodeficiency virus

Introduction

Much of the antiviral activity of antibody is mediated by interactions between the Fc segment of immunoglobulin and Fc receptors (FcRs) present on many different cell types. Such interactions could have a beneficial impact on viral infection through, for example, antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, or trogocytosis (wherein plasma membranes are sheared off of one cell by another cell). However, Fc–FcR interactions may also result in antibody-dependent enhancement of infection, a phenomenon best described with respect to dengue virus infections. In this review, we will focus primarily on ADCC in the setting of HIV-1 and related lentiviral infections and also touch briefly on other potentially beneficial functions. For a discussion of

antibody-dependent enhancement, the interested reader is directed elsewhere [1,2]. In addition, detailed treatments of FcR biology can be found in recent reviews [3,4].

ADCC occurs when antibody forms a bridge between a target cell bearing foreign antigens on its surface and an effector cell, typically a natural killer cell expressing FcRs. The cross-linking of the FcRs initiates a cascade of signals leading to the release of lytic compounds from the effector cell that ultimately result in the lysis of the target cell. Thus, as is the case with cytotoxic T-cell activity, ADCC has the potential to remove cells producing virus. ADCC is best described for IgG interacting with Fc receptors for IgG (FcγRs). However, IgA-FcαR and IgE-FcεR interactions leading to ADCC also occur [5,6].

^aDivision of Infectious Diseases, Department of Medicine, School of Medicine, ^bDepartment of Molecular Biology & Biochemistry, School of Biological Sciences, University of California, Irvine, USA, ^cDepartment of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Centre de Recherche du CHUM, and ^dDepartment of Microbiology and Immunology, McGill University, Montreal, Canada.

Correspondence to Donald N. Forthal, UC Irvine School of Medicine, Irvine, California, 92697, USA.

E-mail: dnfortha@uci.edu

Received: 24 July 2018; accepted: 30 July 2018.

DOI:10.1097/QAD.0000000000002011

Of the IgG subclasses, IgG1 and IgG3 are best at engaging Fc receptors [3,7]. Fc glycosylation can also have a major impact on Fc–FcγR interactions [8]. Finally, polymorphisms in the FcγRs themselves, particularly those in FcγRIIIa and FcγRIIa, can influence the affinity for IgG and the ADCC activity in a subclass-specific manner [7,9].

Antibody-dependent phagocytosis (ADP) occurs when antibody opsonizing a cell or a cell-free pathogen cross-links FcRs on phagocytic cells such as monocytes, macrophages, dendritic cells, or neutrophils. The opsonized cell or pathogen is then internalized and, for the most part, degraded in phagolysosomes. However, FcR-mediated internalization of virus also represents a means of virus entry into susceptible target cells that could potentially result in enhanced infection [10,11]. Using green fluorescent protein (GFP)-expressing HIV-1, it has been shown that virions are poor targets for monocyte-mediated ADP by Env-specific IgG, likely because of the paucity of Env spikes on the virion surface and because of the inability of IgG antibodies to aggregate virus [12]. However, cells decorated with virus on their surface, a state imitating target cells in the process of being infected, may undergo ADP or trogocytosis [12–15]. Whether or not phagocytosis or trogocytosis of such cells, or of infected cells, contributes to virus clearance is unknown.

Apart from functions that result in target cell death, triggering of FcRs by opsonizing antibodies can result in the secretion of various chemokines and cytokines with direct and indirect antiviral and inflammation-modulating effects [16,17]. Finally, the sum total of FcR-triggered effects on virus replication can be measured using the antibody-dependent cell-mediated virus inhibition (ADCVI) assay, in which viral yield is measured after incubating infected lymphocytes with effector cells and antibody [16,18].

Measuring antibody-dependent cellular cytotoxicity: concepts and controversies

Env-coated versus infected target cells

One of the earliest and most widely used techniques to measure anti-HIV ADCC activity relies on the coating of CD4⁺ T cells – either cell lines such as CEM-NKr or primary CD4⁺ T cells – with recombinant Env proteins gp120 or gp140 or with inactivated viral particles [19–32]. Killing of Env-coated target cells is then measured by the release of ⁵¹Cr (chromium release assay) [26,33,34] or by calculating the emergence of prelabeled coated cells that lose a viability dye [rapid fluorometric ADCC (RFADCC) assay] [25,32,35]. ADCC activity has also been evaluated by quantifying the cleavage of a fluorogenic peptide substrate that generates a fluorescent signal when cleaved by granzyme B (ADCC GranToxiLux assay) [27,28,36,37], by detecting intracellular

IFN-γ or cell-surface expression of CD107a or by measuring the loss of intracellular granzyme B [38,39]. Note that these latter assays do not directly measure ADCC but more precisely measure activities that require natural killer effector cell responses similar to those occurring during ADCC.

It is important to consider that Env coating of CD4⁺ T cells is achieved through the interaction of gp120 with the CD4 receptor. Thus, these assays cannot detect activity mediated by antibodies that target the gp120 CD4-binding site (CD4BS) [40–44]. Moreover, gp120-coated cells do not expose quaternary epitopes present in the untriggered Env trimer, and therefore, are not useful to measure ADCC activity mediated by antibodies recognizing such quaternary epitopes (e.g. PG9, PG16, etc.) [45–48]. These considerations and others have led to several approaches to measure ADCC against infected target cells. Such target cells can be made by infecting CD4⁺ T cells, mostly CEM-NKr cells or primary CD4⁺ T cells, with infectious HIV-1 molecular clones (IMCs). However, an overlooked problem of this approach is the intrinsic ability of gp120 to be shed from the surface of infected cells. Shed gp120 binds to uninfected, bystander T cells through a CD4 interaction, thus providing another susceptible target cell population in addition to the infected cells (Fig. 1). This natural phenomenon greatly complicates ADCC measurements. Although infected cells express trimeric Env at their surface, uninfected bystander cells are coated with monomeric gp120. It is, therefore, paramount to discern ADCC responses against infected versus uninfected cells, as anti-Env Abs have different specificities [40]. Indeed, whereas some preferentially recognize monomeric gp120, others only bind the untriggered ‘closed’ trimer (discussed below).

Though natural killer cell activation and GranToxiLux assays fail to differentiate responses against infected versus uninfected cells, other approaches do. Infected cells can easily be identified by performing intracellular p24 staining; ADCC activity is then determined by calculating the loss of the percentage of infected (p24⁺) cells by flow cytometry [36,40,49–55]. Similar flow cytometry approaches use modified IMC coding for reporter genes such as GFP [52,53,56–60]. Another method to measure ADCC activity against the infected cell population is the use of IMCs coding for the luciferase reporter gene (*LucR*). This approach is amenable to high-throughput assays and has been widely used in the field [37,61–74]. However, great caution should be exerted in selecting these reporter IMCs in order to ensure that insertion of the reporter gene does not affect expression of viral proteins, particularly Nef, that play a critical role in protecting infected cells from ADCC responses (detailed below; Fig. 1) [75]. Finally, another luciferase-based method uses a T-cell line encoding a Tat-driven luciferase gene, which allows luciferase to be expressed only upon productive HIV-1 or simian immunodeficiency virus

Fig. 1. HIV-1-infected cells are protected from antibody-dependent cellular cytotoxicity responses. To avoid exposing vulnerable CD4-induced epitopes, HIV-1 controls the level of cell surface CD4 through the action of Nef and Vpu and limits Env accumulation through Vpu-mediated BST-2/tetherin downmodulation (a). In the absence of Nef and/or Vpu, Env and CD4 can interact at the cell surface, thus sensitizing infected cells to ADCC mediated by CD4i Abs (b). An intrinsic property of HIV-1 Env is that its gp120 subunits sheds. This is because of the noncovalent association between gp41 and gp120. Shed gp120 interacts with the CD4 receptor present at the surface of uninfected bystander cells, thus resulting in the exposure of vulnerable epitopes leading to the sensitization of these cells to ADCC responses mediated by CD4i Abs (c). ADCC, antibody-dependent cellular cytotoxicity.

(SIV) infection [76]. As the cell line codes for the reporter gene, unmutated IMCs can be used, and elimination of infected cells is determined by simply calculating the loss of luciferase activity [76]. It is worth noting that this assay, using an unmutated CRF01_AE IMC, was used to identify ADCC as a correlate of protection in the RV144 trial [77].

The role of Env conformation and accessory proteins in antibody-dependent cellular cytotoxicity

The functional Env trimer is highly flexible and transits from its unliganded 'closed' conformation (state 1) to its 'open' CD4-bound (state 3; Fig. 2). Interaction with CD4 induces conformational changes in Env resulting in

Fig. 2. Impact of Env conformation on antibody-dependent cellular cytotoxicity. A small residue at position 375 in the Phe 43 cavity (shown in white) favors a closed (Env state 1) conformation. Larger hydrophobic residues at this position, such as histidine (H375) or mutations in restraining residues such as L193 shift Env to more open conformations. Env interactions with membrane-anchored CD4, because of Nef and/or Vpu deletion, stabilize Env state 3. This conformation is also sampled by monomeric gp120 bound to CD4, present at the surface of gp120-coated cells. Env conformational landscape modulates its opening, and therefore, the exposure of vulnerable epitopes recognized by ADCC-mediating CD4i Abs. ADCC, antibody-dependent cellular cytotoxicity.

the adoption of an intermediate 'partially open' conformation (state 2) followed by state 3 [78–80]. Env flexibility and controlled conformational transitions represent a formidable barrier against antibody attack.

Envs from primary HIV-1 isolates are relatively resistant to easy-to-elicited CD4i Abs, which are predominant in the sera of HIV-1-infected individuals [58,81,82]. This is mostly because of the 'closed' nature of primary Envs,

which primarily sample state 1 [79], thus effectively occluding epitopes recognized by CD4i Abs. CD4 engagement drives Env into states 2/3 and renders it susceptible to CD4i Ab binding [58,59,78,83–85]. In order to avoid exposure of these vulnerable epitopes, Env tightly controls its transition from state 1 to states 2/3. The V1/V2 and V3 loops play a critical role in preventing spontaneous transitions to downstream conformations [86,87]. A conserved 150 Å³ pocket where phenylalanine 43 of CD4 engages with the gp120 can predispose Env to spontaneously assume conformations closer to states 2/3 when it is filled with large hydrophobic residues [84,88], which in turn sensitizes infected cells to ADCC mediated by CD4i Abs [84] (Fig. 2). Although residue S375 is well conserved in the majority of group M HIV-1 isolates, CRF01_AE strains have a naturally occurring histidine at this position (H375); such strains predominate in Thailand. A recent report suggests that the presence of H375 in Thai strains might have contributed to the observed vaccine efficacy of RV144 [84]. Other HIV-1 Env strains have a small residue at position 375 (serine or threonine), and therefore, predominantly sample closed state 1 conformations.

Overall, cells infected with primary viruses and coding for functional Nef and Vpu proteins (see below) are largely resistant to ADCC mediated by CD4i Abs [49,53,56,59,81,89]. Despite the different elements precluding a premature opening of Env, interaction with membrane-bound CD4 results in exposure of vulnerable CD4i epitopes [59]. Consequently, ADCC susceptibility to CD4i Abs is dramatically enhanced when infected cells express Env in its open state 2/3 conformation [58,83,84]. As CD4i Abs are easily elicited and achieve high titers during HIV-1 infection [82], the virus evolved to minimize exposure of this vulnerable Env conformation. HIV-1 limits Env–CD4 interaction by down-regulating CD4 and preventing accumulation of Env [58,59,90–92]. Nef and Vpu accessory proteins reduce accumulation of CD4 at the cell surface [58,59] in a two-step mechanism. First, during the early phases of the HIV-1 replication cycle, Nef downregulates CD4 from the plasma membrane. Second, Vpu, expressed from a bicistronic mRNA also coding for Env, induces CD4 degradation through an endoplasmic reticulum (ER)-associated protein degradation mechanism [93]. The action of Vpu liberates Env from CD4-dependent retention in the ER [94]. Env is then free to traffic to the plasma membrane in a ‘closed’ conformation effectively occluding CD4i epitopes. Hence, several reports have shown that cells infected with viruses defective for Nef and/or Vpu expression are more susceptible to ADCC responses mediated by HIV+ sera or CD4i antibodies [49,57–59,75,91,92,95–98]. In addition to its role in CD4-downregulation, Nef also protects infected cells from ADCC responses by down-regulating the expression of NKG2D ligands (MICA, ULBP1, and ULBP2) [96,99,100], which otherwise

activate natural killer cells by interacting with the NKG2D receptor [95,96]. Therefore, Nef and Vpu accessory proteins protect infected cells from ADCC.

Effector cells

In addition to antigen recognition, antibodies through their Fc segment must engage with specific receptors located at the surface of certain immune effector cells. Receptor engagement is required in order to activate effector cells and trigger the release of perforin and granzyme required to kill the target cell. Most assays have relied on peripheral blood mononuclear cells (PBMC) [40,41,50,51,58,59,65,83,84], natural killer cells isolated from PBMCs [76,81,89,90,95,101,102], or natural killer cell lines [76,81,101,103,104]. Natural killer cell effector functions have been extensively analyzed and are controlled by an equilibrium established between signals delivered through inhibitory (e.g. KIR, CD94/NKG2A), activating (e.g. FcγRIIIa, NKG2D, DNAM-1, NKp46) or co-activating (e.g. NTB-A, 2B4) receptors [105]. The HIV-1 Nef accessory protein decreases NKG2D ligand expression [49,75,96,99,100], and therefore, modulates the activation status of natural killer cells.

Monocytes, macrophages, neutrophils and natural killer cells are also reported to mediate ADCC against HIV-1-infected or Env-coated cells [41,106–108] through the FcγRs expressed on those cells [3]. However, it should be noted that monocytes, macrophages and neutrophils function as phagocytes, presenting a problem in interpreting some assays [14]. Discerning ADCC from antibody-mediated phagocytosis *in vivo* may be particularly difficult [109].

Role of antibody-dependent cellular cytotoxicity and other Fc receptor-mediated functions in preventing infection

It is clear from numerous studies using animal models that antibodies capable of neutralizing a lentivirus challenge strain can prevent infection [110–123]. Thus, developing vaccines that elicit neutralizing antibodies against a broad array of virus strains is a major goal of HIV vaccine development. Although some progress has been made, eliciting broadly neutralizing antibodies by vaccination has largely been unsuccessful. An alternative approach would be to depend on nonneutralizing antibodies that nonetheless are potentially antiviral, such as those mediating ADCC or phagocytosis.

Early studies in monkeys hinted at a role for nonneutralizing antibodies in preventing infection. For example, passive infusion of polyclonal IgG derived from sera of vaccinated and infected monkeys was shown to prevent infection in newborn macaques following oral challenge with SIVmac251 [124]. The IgG was considered to be poorly neutralizing but had substantial ADCVI activity

[125]. However, a subsequent similar study found no protection [126]. Moreover, several studies employing poorly neutralizing polyclonal or monoclonal antibodies with ADCVI and/or ADCC activity failed to prevent infection after intravenous, vaginal or rectal SIV or SHIV challenge [127–133]. One of these studies did, however, offer a glimmer of hope in that fewer transmitted/founder (T/F) strains established infection in monkeys challenged rectally with high-dose SHIV_{BaL} after infusion of a nonneutralizing, ADCC-mediating antibody. Another study found two of five animals that received vaginally delivered F240 did not become infected after SHIV_{162P4} vaginal challenge, but there was no significant difference between the F240-treated and control animals [127]. Moreover, that same study demonstrated an increase in T/F strains after passive parenteral infusion or local application of the nonneutralizing antibody b6 [127]. From a mechanistic standpoint, it is unknown how passively infused antibody could reduce or increase the number of T/F strains without impacting the overall risk of infection; however, it is possible that larger sample sizes could reveal differences in infection risk. A study by Hessel *et al.* [131] compared infusion of IgG1 and IgG3 versions of a nonneutralizing anti-V2i-specific monoclonal antibody in preventing infection after repeated rectal SHIV_{BaL.P4} challenge. There were no significant differences between the IgG1, IgG3 and control antibodies, but the IgG1 version resulted in reduced plasma and PBMC virus levels and decreased viral DNA in lymphoid tissues compared with control antibody. Finally, in a mouse model, a nonneutralizing antibody directed against influenza hemagglutinin cleared cells infected with HIV-1 modified to express hemagglutinin and protected mice against infection; protection was likely mediated through FcγRs [134]. The relevance of this model organism to lentiviral infections in humans and nonhuman primates is unclear.

Studies of the role of ADCC or other FcR-mediated antibody functions in preventing HIV infection in humans also reveal uncertainty but point toward little, if any benefit. ADCVI antibody activity was demonstrated not to be associated with the risk of HIV-1 superinfection [135]. However, ADCC activity of IgG in breast milk (measured by RF-ADCC assay using gp120-coated CEM.NK_r cells) correlated inversely with infant infection risk; maternal plasma ADCC activity was not associated with transmission risk [136]. The same group found that ADCC activity in infant plasma was higher in uninfected than in infected infants, although the difference was not significant [137]; infant plasma ADCC activity did, however, correlate with reduced mortality. In this study, neither breast milk nor maternal plasma ADCC activity (measured by both gp120-coated and HIV-1-infected CEM.NK_r-CCR5 cells) were associated with maternal-to-child transmission [137]. A trial comparing passive immunotherapy with polyclonal IgG (HIVIGLOB) with zidovudine to zidovudine alone in

preventing mother-to-child transmission demonstrated no benefit attributable to HIVIGLOB [138]. Moreover, there was a suggestion, though controversial, that the HIVIGLOB might have increased the rate of infection. HIVIGLOB was able to neutralize some strains of HIV-1, but neither ADCC nor other FcγR-mediated antibody activities in HIVIGLOB were reported [139].

Although studies employing passive infusion do not support the notion that nonneutralizing antibodies, in and of themselves, can prevent infection, vaccine trials in monkeys and humans provide some, albeit nondefinitive, evidence to the contrary. For example, adenovirus-based regimens, particularly, when boosted with Env glycoprotein, offered protection against intrarectal challenge with SIVmac251 [140]. Protection correlated with binding antibody titers as well as with a composite measure of FcγR-mediated and complement-mediated antibody functions; ADCC as well as ADP individually correlated with protection, although the magnitude of the correlation was not reported [140]. It should be noted that ADP was measured using 1 μm beads coated with recombinant gp140, and ADCC was measured by the RF-ADCC assay using CEM-NK_r cells also coated with recombinant gp140; as discussed above, there are questions regarding the relevance of these assays. In another vaccine study using adenovirus-based and modified vaccinia Ankara (MVA)-based vaccines without Env boosting, protection against acquisition after rectal challenge correlated with V2-specific binding antibodies; there was a trend for ADCC activity that did not meet statistical significance after adjusting for multiple comparisons [141]. Vaccine regimens using DNA and/or MVA expressing SIVmac239 sequences provided about 60% per-challenge protection after intrarectal exposure to SIVsme660 [142]. The vaccines elicited serum ADCC activity, which did not correlate with protection [142]. ADCC, measured using cells that express luciferase upon infection, was associated with complete protection following intravenous SIVmac251NE challenge in animals that had been previously immunized with live-attenuated versions of SIVmac239Δnef [101]. Partial protection from vaginal challenge with a different SIVmac251 variant was also associated with serum ADCC activity [101]. gp120-CD4 chimeric subunit protein vaccines gave protection against low-dose repeated rectal challenges with heterologous SHIV_{162P3} or SIVmac251, and protection was shown to correlate with ADCC measured using gp120-coated target cells [143]. A recent study using a pentavalent vaccine otherwise similar to the RV144 immunogen resulted in 55% protection from low-dose repeated rectal SHIV challenge; several antibody assays, including a bead-based phagocytosis assay and ADCC using gp120-coated target cells or cells infected with Nef-defective IMCs correlated with protection [65,144]. Finally, immunization with truncated, trimeric HIV-1 gp41 and the P1 peptide (amino acids 649–683 of gp41) inserted into the lipid membrane of virosomes (a virus-like particle derived

from influenza virus) resulted in a high degree of protection from low-dose, repeated vaginal challenge of Chinese macaques with SHIV_{SF162P3}. Cervicovaginal-secretion ADCC activity, as well as transcytosis-inhibition activity, correlated with protection. Notably, the vaccine regimen did not elicit any circulating ADCC activity [145].

Vaccine trials in humans also provide correlative evidence of a role for FcγR-mediated antibody functions in preventing HIV-1 infection. The first human phase III HIV-1 vaccine trial (VAX004) utilized bivalent recombinant gp120 [146]. Although no protection was demonstrated, higher serum ADCVI activity against a clinical R5 strain of HIV-1 correlated inversely with infection rate [147]. The only human vaccine trial to register vaccine efficacy was the RV144 trial conducted in Thailand [145]. The approximately 30% efficacy allowed an examination of immune correlates, which revealed an association between higher V1/V2 binding antibodies and protection [77]. In addition, higher anti-Env IgA antibodies were associated with a higher rate of infection. In a secondary analysis, higher ADCC activity (using HIV-1_{92TH023}-infected CEM.NKr-CCR5 target cells) was associated with protection, but only after controlling for IgA levels. It should be noted, however, that neutralizing activity against tier 1 HIV-1 was similarly associated with protection after controlling for IgA levels [77]. A subsequent analysis of antibody responses in the RV144 trial revealed that V1/V2 IgG3 antibodies that correlate with lower infection risk also correlate with ADCC activity using gp120-coated or HIV-1_{92TH023}-infected target cells [148].

Whereas animal models have not demonstrated preventive efficacy of nonneutralizing antibodies, there is direct evidence that engagement of FcγRs by IgG is essential for

optimal prevention of SHIV infection by neutralizing antibodies. Thus, Hessel *et al.* [149,150], found that mutations in the neutralizing antibody b12 that abrogated FcγR binding resulted in less protection than wild-type b12 following passive infusion and vaginal SHIV challenge of macaques. Similar conclusions were reached by Bournazos, *et al.* [151] using mouse models and HIV-1. However, a nonfucosylated version of b12, which allowed increased FcγRIIIa binding and greater ADCC (using a natural killer cell line as effectors) and ADCVI (with human PBMCs as effectors) activities *in vitro*, did not improve protection over wild-type b12 after a repeated low-dose vaginal challenge with SHIV_{SF162P3} [152]. ADCVI activity using human monocytes was equivalent between the wild-type and nonfucosylated versions of b12. The lack of improved protection may have been because of already maximum in-vivo FcγR-mediated activity of the wild-type antibody. Alternatively, an FcγR-mediated antibody function other than one involving ADCC due to FcγRIIIa on natural killer cells may be important in the optimal effect of neutralizing antibodies. Finally, a more recent study suggests that FcγR engagement is not always necessary for optimal prevention by a neutralizing antibody: a version of the human mAb PGT121 with the same Fc mutation used in the Hessel study of b12 was equally effective as wild-type PGT121 in preventing intravenous SHIV challenge. Moreover, both versions of the antibody similarly lowered viral loads when used in already infected animals (Stephen Kent, unpublished observation).

In summary, there is little direct evidence in support of nonneutralizing antibodies with antiviral activities such as ADCC having a substantial protective effect (Table 1). The correlative evidence is interesting but the inter-correlations between immune functions and the inability to directly pinpoint a given function or functions in

Table 1. Summary of antibody-dependent cellular cytotoxicity (or other Fc receptor-mediated antibody function) effects on infections with HIV-1 and related viruses.

Impact on infection	Evidence	Results [refs.]
Protecting from acquisition	Passive infusion of nonneutralizing antibodies Correlations with vaccine-elicited antibody responses	Largely negative in preventing infection [124–133] Possible impact on number of transmitted/founder variants [127,130] Reduction of viral load in animals becoming infected [131] ADCC associated with vaccine efficacy in some human and animal vaccine trials [65,77,101,140,144–146,148]
Modulating infection	Passive infusion of nonneutralizing antibodies Correlations with vaccine-elicited antibody responses Correlations with infection-induced responses	Infusion of polyclonal antibody can transiently decrease viremia [158] ADCC activity shown to correlate with reduced viremia levels in some animals studies [154–157] ADCC responses associated with disease progression in animals and humans [26,153,159–161]
Augmenting in-vivo activity of neutralizing antibodies	Passive infusion of neutralizing antibodies	Fc-receptor engagement may improve protective effect of some antibodies and not others [149–151] (unpublished observation) Fc-receptor engagement contributes to reduced viremia in infected animals and humans [164]

prevention makes it difficult to draw conclusions. Fc–FcγR interactions do appear to augment the protective effect of neutralizing antibodies, although the augmented protection may not apply to all antibodies.

The role of antibody-dependent cellular cytotoxicity in modulating infection

There are several studies in both animals and humans suggesting that ADCC plays a role in controlling viremia with HIV, SIV or SHIV. However, most of the studies depend on correlations rather than direct evidence. For example, Banks *et al.* [153] demonstrated a correlation between plasma ADCC activity and progression to AIDS in SIV17E-Br-infected macaques. In a vaccine trial using adenovirus type 5 (Ad5)-expressing SIV recombinants followed by gp120 boosting, serum ADCC activity correlated with low viral burden during the acute phase of infection following intrarectal challenge with SIVmac251 [154]. ADCC in this study was measured using the RF-ADCC assay and chronically SIVmac251-infected H9 target cells. An Ad5-based regimen given intranasally and orally or with the addition of an intratracheal prime, followed by intramuscular Env boosting, resulted in reduced acute viremia following intrarectal challenge with SIVmac251. Reductions in acute viremia correlated with serum ADCC (using gp120-coated CEM-NKr cells) and ADCVI activity (using SIVmac251-infected rhesus PBMCs) [155,156]. Similar findings of reduced viremia following vaccination that correlated with ADCC and ADCVI activity were reported after intravenous challenge with SHIV_{89.6P} [157].

One study did directly show some effect of nonneutralizing antibody on control of viremia, although the effect was weak and transitory. In that study, IgG from SIVmac251-infected animals was infused into other SIVmac251-infected animals deemed to be rapid progressors. The rapid progressors had negligible anti-SIV antibody titers prior to the infusion, but the infusion resulted in a two-fold to three-fold reduction in viremia that began rising after 12 h. The kinetics of the viral load reduction suggested that an effector mechanism, such as ADCC, was responsible [158].

In humans, Baum *et al.* [26] demonstrated an inverse correlation with serum ADCC antibody responses and disease progression (using a chromium-release assay and HIV-1_{MN} gp120-coated cells). Another study focused on the function of natural killer cells to mediate ADCC against cytomegalovirus-infected cells and found an association between higher activity and improved survival [159]. ADCC antibody activities among HIV-infected individuals who control viremia in the absence of antiretroviral therapy (elite controllers) have been reported to be higher when compared with those with

poorer control [160,161]. However, one of these studies found higher ADCC activity in elite controllers only with an assay relying on granzyme B entry into target cells and found no difference when the RF-ADCC assay was used [160]. Although these studies are consistent with a role for FcγR-mediated antibody functions in modulating infection in humans, their correlative nature makes it equally likely that better functions are the result of better viremia control through other mechanisms (Table 1).

Finally, with respect to modulating existing infection, direct evidence in humans indicates that passive infusion of potent bNabs leads to rapid but transient lowering of viral load [162,163]. The fact that clearance of infected cells through an FcγR-mediated process likely contributes to the reduced viremia suggests that neutralizing antibodies with effector functions might be a useful component of strategies aimed to reduce virus reservoirs [164].

Conclusion

The results of the RV144 vaccine trial in Thailand and subsequent evaluations of immune correlates of protection in that trial have generated renewed interest in eliciting antibodies with FcγR-mediated functions to prevent HIV-1 infection. However, studies aimed at directly testing the role for such functions – in the presence of weak neutralizing activity – have been disappointing. HIV-1 appears to have evolved different mechanisms, including Nef and Vpu downregulation of CD4 expression on infected cells and Vpu antagonism of BST-2/tetherin to evade ADCC. Moreover, many antibodies elicited during infection or vaccination that mediate ADCC are directed against CD4i epitopes, which, related to CD4 downregulation, are generally not expressed on infected cells. Although analyses have revealed correlations between ADCC and protection in human and animal vaccine trials (Table 1), it is difficult to ascertain with any degree of certainty whether or not ADCC is actually a key factor in preventing infection. Stronger evidence indicates that FcγR-mediated antibody functions augment the protective effect of neutralizing antibodies, though the exact function(s) playing such a role is unknown. Finally, the impact of FcγR-mediated activities in augmenting the effect of neutralizing antibodies could be a key factor in immunotherapies designed to reduce viral reservoirs.

Acknowledgements

The authors would like to thank Jonathan Richard for helpful comments. D.N.F. is supported by a grant from the National Institute of Allergy and Infectious Diseases under award number R01AI118581. A.F. is the recipient of a Canada Research Chair on Retroviral Entry

(RCHS0235) and is supported by a CIHR foundation grant (352417).

Conflicts of interest

There are no conflicts of interest.

References

- Gorlani A, Forthal DN. **Antibody-dependent enhancement and the risk of HIV infection.** *Curr HIV Res* 2013; **11**:421–426.
- Taylor A, Foo S-S, Bruzzone R, Dinh LV, King NJC, Mahalingam S. **Fc receptors in antibody-dependent enhancement of viral infections.** *Immunol Rev* 2015; **268**:340–364.
- Bournazos S, Ravetch JV. **Fcγ receptor function and the design of vaccination strategies.** *Immunity* 2017; **47**:224–233.
- Kaifu T, Nakamura A. **Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other immune diseases: a general review.** *Int Immunol* 2017; **29**:319–325.
- Lohse S, Loew S, Kretschmer A, Jansen JHM, Meyer S, Ten Broeke T, et al. **Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.** *Br J Haematol* 2018; **181**:413–417.
- Karagiannis SN, Josephs DH, Karagiannis P, Gilbert AE, Saul L, Rudman SM, et al. **Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application.** *Cancer Immunol Immunother* 2012; **61**:1547–1564.
- Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. **Specificity and affinity of human Fcγγ receptors and their polymorphic variants for human IgG subclasses.** *Blood* 2009; **113**:3716–3725.
- Cymer F, Beck H, Rohde A, Reusch D. **Therapeutic monoclonal antibody N-glycosylation - structure, function and therapeutic potential.** *Biol J Int Assoc Biol Stand* 2018; **52**:1–11.
- Bruhns P, Jönsson F. **Mouse and human FcR effector functions.** *Immunol Rev* 2015; **268**:25–51.
- Homsy J, Meyer M, Tateno M, Clarkson S, Levy JA. **The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells.** *Science* 1989; **244**:1357–1360.
- Halstead SB, Chow JS, Marchette NJ. **Immunological enhancement of dengue virus replication.** *Nature New Biol* 1973; **243**:24–26.
- Gach JS, Bouzin M, Wong MP, Chromikova V, Gorlani A, Yu K-T, et al. **Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis.** *PLoS Pathog* 2017; **13**:e1006793.
- Horner H, Frank C, Dechant C, Repp R, Glennie M, Herrmann M, et al. **Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity.** *J Immunol* 2007; **195**:337–345.
- Kramski M, Parsons MS, Stratov I, Kent SJ. **HIV-specific antibody immunity mediated through NK cells and monocytes.** *Curr HIV Res* 2013; **11**:388–406.
- Daubeuf S, Lindorfer MA, Taylor RP, Joly E, Hudrisier D. **The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell.** *J Immunol* 2010; **195**:1897–1908.
- Forthal DN, Landucci G, Daar ES. **Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells.** *J Virol* 2001; **75**:6953–6961.
- Olive A, Kinter AL, Vaccarezza M, Rubbert A, Catanzaro A, Moir S, et al. **Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro.** *J Clin Invest* 1998; **102**:223–231.
- Forthal DN, Landucci G. **In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity.** *J Immunol Methods* 1998; **220**:129–138.
- Rook AH, Lane HC, Folks T, McCoy S, Alter H, Fauci AS. **Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.** *J Immunol* 1987; **150**:1064–1067.
- Ackerman ME, Mikhailova A, Brown EP, Dowell KG, Walker BD, Bailey-Kellogg C, et al. **Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control.** *PLoS Pathog* 2016; **12**:e1005315.
- Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, et al. **Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.** *Sci Transl Med* 2014; **6**:228ra38.
- Parker SJ, Sadlon TA, Gordon DL. **Enhancement of NK cell-mediated antibody-dependent lysis of recombinant gp120-coated CD4 cells by complement.** *J Infect Dis* 1995; **171**:186–189.
- Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, et al. **Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDS VAX B/E prime-boost HIV-1 vaccine trial in Thailand.** *Vaccine* 2005; **23**:2522–2529.
- Gómez-Román VR, Florese RH, Peng B, Montefiori DC, Kalyanaraman VS, Venzon D, et al. **An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against nonsubtype B HIV strains.** *J Acquir Immune Defic Syndr* 2006; **1999**:270–277.
- Gómez-Román VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, et al. **A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity.** *J Immunol Methods* 2006; **308**:53–67.
- Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, et al. **HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression.** *J Immunol* 1996; **195**:2168–2173.
- Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang K-K, et al. **Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.** *J Virol* 2012; **86**:11521–11532.
- Pollara J, Hart L, Brewer F, Pickeral J, Packard BZ, Hoxie JA, et al. **High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses.** *Cytom Part J Int Soc Anal Cytol* 2011; **79**:603–612.
- Madhavi V, Wren LH, Center RJ, Gonelli C, Winnall WR, Parsons MS, et al. **Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design.** *AIDS Lond Engl* 2014; **28**:1859–1870.
- Karlsson I, Borggren M, Jensen SS, Heyndrickx L, Stewart-Jones G, Scarlatti G, et al. **Immunization with clinical HIV-1 Env proteins induces broad antibody dependent cellular cytotoxicity-mediating antibodies in a rabbit vaccination model.** *AIDS Res Hum Retroviruses* 2017. [Epub ahead of print].
- Tolbert WD, Gohain N, Alsaifi N, Van V, Orlandi C, Ding S, et al. **Targeting the late stage of HIV-1 entry for antibody-dependent cellular cytotoxicity: structural basis for Env epitopes in the C11 region.** *Struct Lond Engl* 2017; **1993**:1719.e4–1731.e4.
- Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, et al. **Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.** *Proc Natl Acad Sci U S A* 2013; **110**:E69–E78.
- Tomescu C, Mavilio D, Montaner LJ. **Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKG2D and NKG2D.** *AIDS Lond Engl* 2015; **29**:1767–1773.
- Tyler DS, Stanley SD, Nastala CA, Austin AA, Bartlett JA, Stine KC, et al. **Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects.** *J Immunol* 1990; **150**:3375–3384.
- Orlandi C, Flinko R, Lewis GK. **A new cell line for high throughput HIV-specific antibody-dependent cellular cytotoxicity (ADCC) and cell-to-cell virus transmission studies.** *J Immunol Methods* 2016; **433**:51–58.

36. Smalls-Mantey A, Doria-Rose N, Klein R, Patamawenu A, Migueles SA, Ko S-Y, et al. **Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.** *J Virol* 2012; **86**:8672–8680.
37. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, et al. **An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.** *J Virol* 2011; **85**:7029–7036.
38. Sun Y, Asmal M, Lane S, Permar SR, Schmidt SD, Mascola JR, et al. **Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys.** *J Virol* 2011; **85**:6906–6912.
39. Stratov I, Chung A, Kent SJ. **Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects.** *J Virol* 2008; **82**:5450–5459.
40. Richard J, Prévost J, Baxter AE, von Bredow B, Ding S, Medjahed H, et al. **Uninfected bystander cells impact the measurement of HIV-specific antibody-dependent cellular cytotoxicity responses.** *MBio* 2018; **9**:pii: e00358-18.
41. Richard J, Veillette M, Batrville L-A, Coutu M, Chapleau J-P, Bonsignori M, et al. **Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses.** *J Virol Methods* 2014; **208**:107–114.
42. Julien J-P, Sok D, Khayat R, Lee JH, Doores KJ, Walker LM, et al. **Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans.** *PLoS Pathog* 2013; **9**:e1003342.
43. Thali M, Furman C, Ho DD, Robinson J, Tilley S, Pinter A, et al. **Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.** *J Virol* 1992; **66**:5635–5641.
44. Wu X, Yang Z-Y, Li Y, Hogerkor C-M, Schief WR, Seaman MS, et al. **Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.** *Science* 2010; **329**:856–861.
45. Blattner C, Lee JH, Slieden K, Derking R, Falkowska E, de la Peña AT, et al. **Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.** *Immunity* 2014; **40**:669–680.
46. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, et al. **Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.** *Nature* 2014; **509**:55–62.
47. Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, et al. **Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.** *Nature* 2014; **515**:138–142.
48. Walker LM, Phogat SK, Chan-Hui P-Y, Wagner D, Phung P, Goss JL, et al. **Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.** *Science* 2009; **326**:285–289.
49. Alsahafi N, Ding S, Richard J, Markle T, Brassard N, Walker B, et al. **Nef proteins from HIV-1 elite controllers are inefficient at preventing antibody-dependent cellular cytotoxicity.** *J Virol* 2015; **90**:2993–3002.
50. Richard J, Pacheco B, Gohain N, Veillette M, Ding S, Alsahafi N, et al. **Co-receptor binding site antibodies enable CD4-mimetics to expose conserved anticytotoxicity A ADCC epitopes on HIV-1 envelope glycoproteins.** *EBioMedicine* 2016; **12**:208–218.
51. Richard J, Prévost J, von Bredow B, Ding S, Brassard N, Medjahed H, et al. **BST-2 expression modulates small CD4-mimetic sensitization of HIV-1-infected cells to antibody-dependent cellular cytotoxicity.** *J Virol* 2017; **91**: pii: e00219-17.
52. Richard J, Veillette M, Brassard N, Iyer SS, Roger M, Martin L, et al. **CD4 mimetics sensitize HIV-1-infected cells to ADCC.** *Proc Natl Acad Sci U S A* 2015; **112**:E2687–2694.
53. Richard J, Veillette M, Ding S, Zoubchenok D, Alsahafi N, Coutu M, et al. **Small CD4 mimetics prevent HIV-1 uninfected bystander CD4 + T cell killing mediated by antibody-dependent cell-mediated cytotoxicity.** *EBioMedicine* 2016; **3**:122–134.
54. Mujib S, Liu J, Rahman N-, Schwartz JA, Bonner P, Yue FY, et al. **Comprehensive cross-clade characterization of antibody-mediated recognition, complement-mediated lysis, and cell-mediated cytotoxicity of HIV-1 envelope-specific antibodies toward eradication of the HIV-1 reservoir.** *J Virol* 2017; **91**:pii: e00634-17.
55. Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K, et al. **Elimination of HIV-1-infected cells by broadly neutralizing antibodies.** *Nat Commun* 2016; **7**:10844.
56. Ding S, Veillette M, Coutu M, Prévost J, Scharf L, Bjorkman PJ, et al. **A highly conserved residue of the HIV-1 gp120 inner domain is important for antibody-dependent cellular cytotoxicity responses mediated by anticytotoxicity A antibodies.** *J Virol* 2016; **90**:2127–2134.
57. Pham TNQ, Lukhele S, Hajjar F, Routy J-P, Cohen ÉA. **HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2.** *Retrovirology* 2014; **11**:15.
58. Veillette M, Coutu M, Richard J, Batrville L-A, Dagher O, Bernard N, et al. **The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals.** *J Virol* 2015; **89**:545–551.
59. Veillette M, Désormeaux A, Medjahed H, Gharsallah N-E, Coutu M, Baalwa J, et al. **Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity.** *J Virol* 2014; **88**:2633–2644.
60. Pham TNQ, Lukhele S, Dallaire F, Perron G, Cohen ÉA. **Enhancing virion tethering by BST2 sensitizes productively and latently HIV-infected T cells to ADCC mediated by broadly neutralizing antibodies.** *Sci Rep* 2016; **6**:37225.
61. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao H-X, Pollara J, et al. **Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.** *Proc Natl Acad Sci U S A* 2013; **110**:9019–9024.
62. Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, Hwang K-K, et al. **HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.** *J Virol* 2014; **88**:7715–7726.
63. Permar SR, Fong Y, Vandergrift N, Fouda GG, Gilbert P, Parks R, et al. **Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.** *J Clin Invest* 2015; **125**:2702–2706.
64. Sung JAM, Pickeral J, Liu L, Stanfield-Oakley SA, Lam C-YK, Garrido C, et al. **Dual-affinity re-targeting proteins direct T cell-mediated cytotoxicity of latently HIV-infected cells.** *J Clin Invest* 2015; **125**:4077–4090.
65. Bradley T, Pollara J, Santra S, Vandergrift N, Pittala S, Bailey-Kellogg C, et al. **Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.** *Nat Commun* 2017; **8**:15711.
66. Huang Y, Ferrari G, Alter G, Forthal DN, Kappes JC, Lewis GK, et al. **Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.** *J Immunol* 2016; **195**:4603–4612.
67. Viegas EO, Tembe N, Nilsson C, Meggi B, Maueia C, Augusto O, et al. **Intradermal HIV-1 DNA immunization using needle-free Zetajet injection followed by HIV-modified Vaccinia Virus Ankara vaccination is safe and immunogenic in Mozambican young adults: a phase I randomized controlled trial.** *AIDS Res Hum Retroviruses* 2017[Epub ahead of print].
68. Meyerhoff RR, Searce RM, Ogburn DF, Lockwood B, Pickeral J, Kuraoka M, et al. **HIV-1 consensus envelope-induced broadly binding antibodies.** *AIDS Res Hum Retroviruses* 2017; **33**:859–868.
69. Joachim A, Munseri PJ, Nilsson C, Bakari M, Aboud S, Lya-muya EF, et al. **Three-year durability of immune responses induced by HIV-DNA and HIV-modified Vaccinia Virus Ankara and effect of a late HIV-modified Vaccinia Virus Ankara boost in Tanzanian volunteers.** *AIDS Res Hum Retroviruses* 2017; **33**:880–888.
70. Costa MR, Pollara J, Edwards RW, Seaman MS, Gorny MK, Montefiori DC, et al. **Fc receptor-mediated activities of Env-specific human monoclonal antibodies generated from volunteers receiving the DNA prime-protein boost HIV vaccine DP6-001.** *J Virol* 2016; **90**:10362–10378.

71. Joachim A, Bauer A, Joseph S, Geldmacher C, Munseri PJ, Aboud S, *et al.* **Boosting with subtype C CN54rgp140 protein adjuvanted with glucopyranosyl lipid adjuvant after priming with HIV-DNA and HIV-MVA is safe and enhances immune responses: a phase I trial.** *PLoS One* 2016; **11**:e0155702.
72. Wise MC, Hutnick NA, Pollara J, Myles DJF, Williams C, Yan J, *et al.* **An enhanced synthetic multiclade DNA prime induces improved cross-clade-reactive functional antibodies when combined with an adjuvanted protein boost in nonhuman primates.** *J Virol* 2015; **89**:9154–9166.
73. Dennison SM, Anasti KM, Jaeger FH, Stewart SM, Pollara J, Liu P, *et al.* **Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide.** *J Virol* 2014; **88**:9406–9417.
74. Pollara J, McGuire E, Fouda GG, Rountree W, Eudailey J, Overman RG, *et al.* **Association of HIV-1 envelope-specific breast milk IgA responses with reduced risk of postnatal mother-to-child transmission of HIV-1.** *J Virol* 2015; **89**:9952–9961.
75. Prévost J, Richard J, Medjahed H, Alexander A, Jones J, Kappes JC, *et al.* **Incomplete downregulation of CD4 expression affects HIV-1 Env conformation and antibody-dependent cellular cytotoxicity responses.** *J Virol* 2018; **92**:pii: e00484-18.
76. Alpert MD, Heyer LN, Williams DEJ, Harvey JD, Greenough T, Allhorn M, *et al.* **A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays.** *J Virol* 2012; **86**:12039–12052.
77. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, *et al.* **Immune-correlates analysis of an HIV-1 vaccine efficacy trial.** *N Engl J Med* 2012; **366**:1275–1286.
78. Herschhorn A, Ma X, Gu C, Ventura JD, Castillo-Menendez L, Melillo B, *et al.* **Release of gp120 restraints leads to an entry-competent intermediate state of the HIV-1 envelope glycoproteins.** *mBio* 2016; **7**:pii: e01598-16.
79. Munro JB, Gorman J, Ma X, Zhou Z, Arthos J, Burton DR, *et al.* **Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions.** *Science* 2014; **346**:759–763.
80. Ma X, Lu M, Gorman J, Terry DS, Hong X, Zhou Z, *et al.* **HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations.** *eLife* 2018; **7**:pii: e34271.
81. von Bredow B, Arias JF, Heyer LN, Moldt B, Le K, Robinson JE, *et al.* **Comparison of antibody-dependent cell-mediated cytotoxicity and virus neutralization by HIV-1 Env-specific monoclonal antibodies.** *J Virol* 2016; **90**:6127–6139.
82. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, *et al.* **Antigenic conservation and immunogenicity of the HIV coreceptor binding site.** *J Exp Med* 2005; **201**:1407–1419.
83. Prévost J, Richard J, Ding S, Pacheco B, Charlebois R, Hahn BH, *et al.* **Envelope glycoproteins sampling states 2/3 are susceptible to ADCC by sera from HIV-1-infected individuals.** *Virology* 2018; **515**:38–45.
84. Prévost J, Zoubchenok D, Richard J, Veillette M, Pacheco B, Coutu M, *et al.* **Influence of the envelope gp120 Phe 43 cavity on HIV-1 sensitivity to antibody-dependent cell-mediated cytotoxicity responses.** *J Virol* 2017; **91**:pii: e02452-16.
85. Madani N, Princiotta AM, Zhao C, Jahanbakhshsefidi F, Mertens M, Herschhorn A, *et al.* **Activation and inactivation of primary human immunodeficiency virus envelope glycoprotein trimers by CD4-mimetic compounds.** *J Virol* 2017; **91**:pii: e01880-16.
86. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, Moore LR, *et al.* **Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops.** *Proc Natl Acad Sci U S A* 2012; **109**:5663–5668.
87. Liu J, Bartsaghi A, Borgnia MJ, Sapiro G, Subramaniam S. **Molecular architecture of native HIV-1 gp120 trimers.** *Nature* 2008; **455**:109–113.
88. Xiang S-H, Kwong PD, Gupta R, Rizzuto CD, Casper DJ, Wyatt R, *et al.* **Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.** *J Virol* 2002; **76**:9888–9899.
89. Bruel T, Guivel-Benhassine F, Lorin V, Lortat-Jacob H, Baleux F, Bourdic K, *et al.* **Lack of ADCC breadth of human non-neutralizing anti-HIV-1 antibodies.** *J Virol* 2017; **91**:pii: e02440-16.
90. von Bredow B, Arias JF, Heyer LN, Gardner MR, Farzan M, Rakasz EG, *et al.* **Envelope glycoprotein internalization protects human and simian immunodeficiency virus-infected cells from antibody-dependent cell-mediated cytotoxicity.** *J Virol* 2015; **89**:10648–10655.
91. Alvarez RA, Hamlin RE, Monroe A, Moldt B, Hotta MT, Rodriguez Caprio G, *et al.* **HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells.** *J Virol* 2014; **88**:6031–6046.
92. Arias JF, Heyer LN, von Bredow B, Weisgrau KL, Moldt B, Burton DR, *et al.* **Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity.** *Proc Natl Acad Sci U S A* 2014; **111**:6425–6430.
93. Magadán JG, Pérez-Victoria FJ, Sougrat R, Ye Y, Strebel K, Bonifacio JS. **Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps.** *PLoS Pathog* 2010; **6**:e1000869.
94. Kimura T, Nishikawa M, Ohyama A. **Intracellular membrane traffic of human immunodeficiency virus type 1 envelope glycoproteins: vpu liberates Golgi-targeted gp160 from CD4-dependent retention in the endoplasmic reticulum.** *J Biochem (Tokyo)* 1994; **115**:1010–1020.
95. Parsons MS, Richard J, Lee WS, Vandervan H, Grant MD, Finzi A, *et al.* **NKG2D acts as a co-receptor for natural killer cell-mediated anti-HIV-1 antibody-dependent cellular cytotoxicity.** *AIDS Res Hum Retroviruses* 2016; **32**:1089–1096.
96. Alsaifi N, Richard J, Prévost J, Coutu M, Brassard N, Parsons MS, *et al.* **Impaired downregulation of NKG2D ligands by Nef proteins from elite controllers sensitizes HIV-1-infected cells to antibody-dependent cellular cytotoxicity.** *J Virol* 2017;91e00109-17.
97. Batrville L-A, Richard J, Veillette M, Labbé A-C, Alary M, Guédou F, *et al.* **Short communication: anti-HIV-1 envelope immunoglobulin Gs in blood and cervicovaginal samples of Beninese commercial sex workers.** *AIDS Res Hum Retroviruses* 2014; **30**:1145–1149.
98. Tokarev A, Stoneham C, Lewinski MK, Mukim A, Deshmukh S, Vollbrecht T, *et al.* **Pharmacologic inhibition of Nedd8 activation enzyme exposes CD4-induced epitopes within env on cells expressing HIV-1.** *J Virol* 2015; **90**:2486–2502.
99. Cerboni C, Neri F, Casartelli N, Zingoni A, Cosman D, Rossi P, *et al.* **Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity.** *J Gen Virol* 2007; **88**:242–250.
100. Norman JM, Mashiba M, McNamara LA, Onafuwa-Nuga A, Chiari-Fort E, Shen W, *et al.* **The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells.** *Nat Immunol* 2011; **12**:975–983.
101. Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M, Carville A, *et al.* **ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge.** *PLoS Pathog* 2012; **8**:e1002890.
102. Parsons MS, Loh L, Gooneratne S, Center RJ, Kent SJ. **Role of education and differentiation in determining the potential of natural killer cells to respond to antibody-dependent stimulation.** *AIDS Lond Engl* 2014; **28**:2781–2786.
103. Parsons MS, Wren L, Isitman G, Navis M, Stratov I, Bernard NF, *et al.* **HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti-HIV antibody-dependent cellular cytotoxicity.** *J Virol* 2012; **86**:4488–4495.
104. Wren L, Parsons MS, Isitman G, Center RJ, Kelleher AD, Stratov I, *et al.* **Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells.** *PLoS One* 2012; **7**:e38580.
105. Lanier LL. **Up on the tightrope: natural killer cell activation and inhibition.** *Nat Immunol* 2008; **9**:495–502.
106. Smalls-Mantey A, Connors M, Sattentau QJ. **Comparative efficiency of HIV-1-infected T cell killing by NK cells, monocytes and neutrophils.** *PLoS One* 2013; **8**:e74858.

107. Orlikowsky TW, Wang ZQ, Dudhane A, Dannecker GE, Niethammer D, Wormser GP, *et al.* **Dexamethasone inhibits CD4 T cell deletion mediated by macrophages from human immunodeficiency virus-infected persons.** *J Infect Dis* 2001; **184**:1328–1330.
108. Worley MJ, Fei K, Lopez-Denman AJ, Kelleher AD, Kent SJ, Chung AW. **Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC.** *J Immunol Methods* 2018; **457**:41–52.
109. Gordan S, Biburger M, Nimmerjahn F. **blgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.** *Immunol Rev* 2015; **268**:52–65.
110. Safrit JT, Fung MS, Andrews CA, Braun DG, Sun WN, Chang TW, *et al.* **hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120.** *AIDS Lond Engl* 1993; **7**:15–21.
111. Parren PW, Ditzel HJ, Gulizia RJ, Binley JM, Barbas CF, Burton DR, *et al.* **Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.** *AIDS Lond Engl* 1995; **9**:F1–F6.
112. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayeahunie S, *et al.* **Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.** *Nat Med* 2000; **6**:200–206.
113. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, *et al.* **Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.** *Nat Med* 2000; **6**:207–210.
114. Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, *et al.* **A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.** *Nature* 2016; **533**:105–109.
115. Parren PW, Marx PA, Hessel AJ, Luckay A, Harouse J, Cheng-Mayer C, *et al.* **Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.** *J Virol* 2001; **75**:8340–8347.
116. Hessel AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, *et al.* **Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.** *PLoS Pathog* 2009; **5**:e1000433.
117. Hessel AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, *et al.* **Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.** *J Virol* 2010; **84**:1302–1313.
118. Moldt B, Rakasz EG, Schultz N, Chan-Hui P-Y, Swiderek K, Weisgrau KL, *et al.* **Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.** *Proc Natl Acad Sci U S A* 2012; **109**:18921–18925.
119. Pegu A, Yang Z, Boyington JC, Wu L, Ko S-Y, Schmidt SD, *et al.* **Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.** *Sci Transl Med* 2014; **6**:243ra88.
120. Rudicell RS, Kwon YD, Ko S-Y, Pegu A, Louder MK, Georgiev IS, *et al.*, NISC Comparative Sequencing Program. **Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.** *J Virol* 2014; **88**:12669–12682.
121. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, *et al.* **Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.** *Nat Med* 1999; **5**:204–210.
122. Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, Buckler C, *et al.* **Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.** *Proc Natl Acad Sci U S A* 2003; **100**:15131–15136.
123. Ferrantelli F, Rasmussen RA, Buckley KA, Li P-L, Wang T, Montefiori DC, *et al.* **Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies.** *J Infect Dis* 2004; **189**:2167–2173.
124. Rompay VAKK, Berardi CJ, Dillard-Telm S, Tarara RP, Canfield DR, *et al.* **Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection.** *J Infect Dis* 1998; **177**:1247–1259.
125. Forthal DN, Landucci G, Cole KS, Marthas M, Becerra JC, Van Rompay K. **Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.** *J Virol* 2006; **80**:9217–9225.
126. Florese RH, Rompay KKA, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, *et al.* **Evaluation of passively transferred, non-neutralizing antibody-dependent cellular cytotoxicity-mediating igg in protection of neonatal rhesus macaques against oral SIVmac251 challenge.** *J Immunol* 2006; **177**:4028–4036.
127. Burton DR, Hessel AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, *et al.* **Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.** *Proc Natl Acad Sci U S A* 2011; **108**:11181–11186.
128. Dugast A-S, Chan Y, Hoffner M, Licht A, Nkolola J, Li H, *et al.* **Lack of protection following passive transfer of polyclonal highly functional low-dose nonneutralizing antibodies.** *PLoS One* 2014; **9**:e97229.
129. Moog C, Dereuddre-Bosquet N, Teillaud J-L, Biedma ME, Holl V, Van Ham G, *et al.* **Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.** *Mucosal Immunol* 2014; **7**:46–56.
130. Santra S, Tomaras GD, Warrier R, Nicely NI, Liao H-X, Pollara J, *et al.* **Human nonneutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques.** *PLOS Pathog* 2015; **11**:e1005042.
131. Hessel AJ, Shapiro MB, Powell R, Malherbe DC, McBurney SP, Pandey S, *et al.* **Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated simian/human immunodeficiency virus challenges.** *J Virol* 2018; **92**:e02198–e02217.
132. Siegel F, Kurth R, Norley S. **Neither whole inactivated virus immunogen nor passive immunoglobulin transfer protects against SIVagm infection in the African green monkey natural host.** *J Acquir Immune Defic Syndr Hum Retrovirology* 1995; **8**:217–226.
133. Astronomo RD, Santra S, Ballweber-Fleming L, Westerberg KG, Mach L, Hensley-McBain T, *et al.* **Neutralization takes precedence over IgG or IgA isotype-related functions in mucosal HIV-1 antibody-mediated protection.** *EBioMedicine* 2016; **14**:97–111.
134. Horwitz JA, Bar-On Y, Lu C-L, Fera D, Lockhart AAK, Lorenzi JCC, *et al.* **Nonneutralizing antibodies alter the course of HIV-1 infection in vivo.** *Cell* 2017; **170**:637.e10–648.e10.
135. Forthal DN, Landucci G, Chohan B, Richardson BA, McClelland RS, Jaoko W, *et al.* **Antibody-dependent cell-mediated virus inhibition (ADCVI) antibody activity does not correlate with risk of HIV-1 superinfection.** *J Acquir Immune Defic Syndr* 2013; **1999**:31–33.
136. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. **HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads.** *PLOS Pathog* 2012; **8**:e1002739.
137. Milligan C, Richardson BA, John-Stewart G, Nduati R, Overbaugh J. **Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality.** *Cell Host Microbe* 2015; **17**:500–506.
138. Onyango-Makumbi C, Omer SB, Mubiru M, Moulton LH, Nakabiito C, Musoke P, *et al.* **Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY).** *J Acquir Immune Defic Syndr* 2011; **1999**:399–407.

139. Guay LA, Musoke P, Hom DL, Nakabiito C, Bagenda D, Fletcher CV, *et al.* **Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda.** *AIDS Lond Engl* 2002; **16**:1391–1400.
140. Barouch DH, Alter G, Broge T, Linde C, Ackerman ME, Brown EP, *et al.* **Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.** *Science* 2015; **349**:320–324.
141. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, *et al.* **Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.** *Nature* 2012; **482**:89–93.
142. Lai L, Kwa S-F, Kozlowski PA, Montefiori DC, Nolen TL, Hudgens MG, *et al.* **SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.** *Vaccine* 2012; **30**:1737–1745.
143. Fouts TR, Bagley K, Prado IJ, Bobb KL, Schwartz JA, Xu R, *et al.* **Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.** *Proc Natl Acad Sci U S A* 2015; **112**:E992–E999.
144. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, *et al.*, MOPH-TAVEG Investigators. **Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.** *N Engl J Med* 2009; **361**:2209–2220.
145. Bomsel M, Tudor D, Drillet A-S, Alfsen A, Ganor Y, Roger M-G, *et al.* **Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges.** *Immunity* 2011; **34**:269–280.
146. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, *et al.* **Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.** *J Infect Dis* 2005; **191**:654–665.
147. Forthal DN, Gilbert PB, Landucci G, Phan T. **Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate.** *J Immunol* 2007; **1950**:6596–6603.
148. Yates NL, Liao H-X, Fong Y, deCamp A, Vandergrift NA, Williams WT, *et al.* **Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.** *Sci Transl Med* 2014; **6**:228ra39.
149. Hessel AJ, Hangartner L, Hunter M, Havenith CEG, Beurskens FJ, Bakker JM, *et al.* **Fc receptor but not complement binding is important in antibody protection against HIV.** *Nature* 2007; **449**:101–104.
150. Hessel AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, *et al.* **Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.** *Nat Med* 2009; **15**:951–954.
151. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. **Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.** *Cell* 2014; **158**:1243–1253.
152. Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, *et al.* **A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.** *J Virol* 2012; **86**:6189–6196.
153. Banks ND, Kinsey N, Clements J, Hildreth JEK. **Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS.** *AIDS Res Hum Retroviruses* 2002; **18**:1197–1205.
154. Gómez-Román VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R, *et al.* **Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251.** *J Immunol* 2005; **1950**:2185–2189.
155. Hidayat R, Xiao P, Zhou Q, Venzon D, Summers LE, Kalyanaraman VS, *et al.* **Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.** *J Virol* 2009; **83**:791–801.
156. Xiao P, Patterson LJ, Kuete S, Brocca-Cofano E, Thomas MA, Venzon D, *et al.* **Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge.** *J Virol* 2012; **86**:4644–4657.
157. Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, Kozlowski PA, *et al.* **Multiple vaccine-elicited nonneutralizing anti-envelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.** *J Virol* 2010; **84**:7161–7173.
158. Binley JM, Clas B, Gettie A, Vesanen M, Montefiori DC, Sawyer L, *et al.* **Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia.** *Virology* 2000; **270**:237–249.
159. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, *et al.* **Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients.** *J Infect Dis* 1999; **180**:1338–1341.
160. Madhavi V, Wines BD, Amin J, Emery S, Lopez E, Kelleher A, *et al.* **HIV-1 Env- and Vpu-Specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV.** *J Virol* 2017; **91**:pii: e00700-17.
161. Lambotte O, Ferrari G, Moog C, Yates NL, Liao H-X, Parks RJ, *et al.* **Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers.** *AIDS Lond Engl* 2009; **23**:897–906.
162. Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, *et al.* **Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.** *Nat Med* 2017; **23**:185–191.
163. Caskey M, Klein F, Lorenzi JCC, Seaman MS, West AP, Buckley N, *et al.* **Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.** *Nature* 2015; **522**:487–491.
164. Lu C-L, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, *et al.* **Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.** *Science* 2016; **352**:1001–1004.